Skip to main content

Table 4 Relationship between the willingness toward drug susceptibility genetic studies and the attitudes toward genome studies from Logistic Regression Analysis

From: Experiences and attitudes of residents regarding a community-based genome cohort study in Japan: a population-based, cross-sectional study

  Male (n=704 ) Female (n=769)
Willingness toward drug susceptibility genetic studies     Willingness toward drug susceptibility genetic studies    
Yes (n=339) Neutral or No (n=348) ORa 95 % CI P-value Yes (n=360) Neutral or No (n=391) ORa 95 % CI P-value
n (%) n (%)     n (%) n (%)    
High awareness of the Nagahama study 131 (38.9) 77 (22.5) 2.06 1.40–3.03 <0.001 200 (56.0) 178 (46.4) 1.28 0.92–1.79 0.150
Self-rated understanding of terminology
 High 162 (47.9) 88 (25.3) 1    117 (32.8) 67 (17.5) 1   
 Middle 120 (35.5) 124 (35.6) 0.58 0.39–0.87 0.008 148 (41.5) 119 (31.2) 0.81 0.53–1.22 0.307
 Low 56 (16.6) 136 (39.1) 0.33 0.20–0.54 <0.001 92 (25.8) 196 (51.3) 0.35 0.22–0.55 <0.001
The use of genetic information is helpful for disease treatment 311 (94.0) 241 (71.9) 3.41 1.93–6.01 <0.001 317 (90.1) 272 (76.0) 2.51 1.54–4.07 <0.001
Concerns
 Financial infusion 268 (82.5) 247 (74.6) 0.98 0.60–1.60 0.941 280 (80.2) 260 (73.2) 0.90 0.59–1.38 0.629
 Privacy concerns 199 (60.9) 197 (59.3) 0.93 0.59–1.45 0.739 200 (56.7) 190 (52.9) 0.94 0.63–1.40 0.762
Discriminations 139 (42.0) 147 (44.3) 0.83 0.53–1.28 0.289 145 (41.2) 127 (35.7) 1.17 0.78–1.75 0.459
 Unexpected negative effects 131 (39.7) 133 (39.9) 1.09 0.70–1.70 0.696 117(33.1) 112 (31.1) 0.97 0.63–1.49 0.891
 Cloned human beings 114 (34.5) 122 (36.9) 0.85 0.54–1.34 0.934 143 (40.7) 137 (38.3) 1.04 0.67–1.61 0.872
Belief
 Company or government 161 (49.4) 137 (41.4) 1.32 0.89–1.94 0.167 143 (40.7) 137 (38.3) 0.89 0.61–1.29 0.529
  1. aAdjusted according to age and formal education duration